These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38716219)

  • 1. Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379).
    Almhanna K; Breakstone R; Raufi A; Wood R; Webber A; Dionson S; Cavanagh L; Seyhan AA; Safran H; El-Deiry W
    Transl Gastroenterol Hepatol; 2024; 9():15. PubMed ID: 38716219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
    J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
    Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW
    Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
    JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
    Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
    ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
    Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
    Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
    Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
    BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
    Stein MN; Malhotra J; Tarapore RS; Malhotra U; Silk AW; Chan N; Rodriguez L; Aisner J; Aiken RD; Mayer T; Haffty BG; Newman JH; Aspromonte SM; Bommareddy PK; Estupinian R; Chesson CB; Sadimin ET; Li S; Medina DJ; Saunders T; Frankel M; Kareddula A; Damare S; Wesolowsky E; Gabel C; El-Deiry WS; Prabhu VV; Allen JE; Stogniew M; Oster W; Bertino JR; Libutti SK; Mehnert JM; Zloza A
    J Immunother Cancer; 2019 May; 7(1):136. PubMed ID: 31118108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
    Akce M; Farran B; Switchenko JM; Rupji M; Kang S; Khalil L; Ruggieri-Joyce A; Olson B; Shaib WL; Wu C; Alese OB; Diab M; Lesinski GB; El-Rayes BF
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
    Fakih M; Raghav KPS; Chang DZ; Larson T; Cohn AL; Huyck TK; Cosgrove D; Fiorillo JA; Tam R; D'Adamo D; Sharma N; Brennan BJ; Wang YA; Coppieters S; Zebger-Gong H; Weispfenning A; Seidel H; Ploeger BA; Mueller U; Oliveira CSV; Paulson AS
    EClinicalMedicine; 2023 Apr; 58():101917. PubMed ID: 37090438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
    Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
    Awad MM; Le Bruchec Y; Lu B; Ye J; Miller J; Lizotte PH; Cavanaugh ME; Rode AJ; Dumitru CD; Spira A
    Front Oncol; 2021; 11():696512. PubMed ID: 34552864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.
    Bessudo A; Haseeb AM; Reeves JA; Zhu X; Wong L; Giranda V; Suttner L; Liu F; Chatterjee M; Sharma S
    Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38942693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
    Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
    Silk AW; Saraiya B; Groisberg R; Chan N; Spencer K; Girda E; Shih W; Palmeri M; Saunders T; Berman RM; Coric V; Chen S; Zloza A; Vieth J; Mehnert JM; Malhotra J
    Eur J Med Res; 2022 Jul; 27(1):107. PubMed ID: 35780243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.